MitoCareX Bio
Business Services · 11-50 Employees
View Company Info for Free
Overview
Website
www.mitocarexbio.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About MitoCareX Bio
MitoCareX Bio is a drug discovery company focused on developing novel therapies for hard-to-treat resistant cancers by targeting mitochondrial carriers. Utilizing their cloud-based computational chemistry platform and the MITOLINE algorithm, they model and predict small molecules that interact with these carriers. The company aims to address the limited drug discovery projects in this field by generating reliable 3D models for mitochondrial proteins and screening small molecules against them. Founded in 2022, MitoCareX Bio is dedicated to transforming oncology drug development through advanced computational capabilities.Explore more
Popular SearchesMitoCareX Bio LtdSIC Code 87,873NAICS Code 54,541Show moreMitoCareX Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MitoCareX Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if MitoCareX Bio is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
MitoCareX Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once MitoCareX Bio has new funding data
Click to see if MitoCareX Bio had a recent Job posting/layoffs
Earning: See what the market has to say on MitoCareX Bio recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at MitoCareX Bio
Check if MitoCareX Bio has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when MitoCareX Bio launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
MitoCareX Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
MitoCareX Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about MitoCareX Bio.
MitoCareX Bio Tech Stack
A closer look at the technologies used by MitoCareX Bio
See more technologies
MitoCareX Bio News & Media
Nexentis Technologies Announces International AI Drug Discovery Initiative Between MitoCareX Bio and Boltz to Accelerate Novel SLC Small-Molecule Discovery
MITOLINE®-Enabled 3D Structural Modeling and Boltz AI Capabilities to Be Combined by MitoCareX in a Synergistic Virtual Screening Campaign for selected Transporter TargetsNexentis: Subsidiary MitoCareX Bio Successfully Completed Broad Analysis of SLC Transport Proteins to Support Discovery of Hard-to-Treat Cancers and Metabolic Diseases
Ness Ziona, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), today reported that it has completed a broad structural analysis of human SLC (Solute Carrier) transport proteins as part of its ongoing efforts to expand andNexentis Announces MitoCareX Bio Achieves Key R&D Milestone, Generating a Substantially Improved Hit Molecule on the Path to Pre-Clinical Development
Ness Ziona, Israel, May 18, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company"), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has successfully achieved its first drug discovery milestone since its acquisition by Nexentis: the generation of an optimized hit molecule with substantially improved pharmaNexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™
Neve Yarak, Israel, May 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS), (“Nexentis” or the “Company”), a drug discovery company that is also invests in solar energy assets based on the RTB (Ready to Build) business model, today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. (“MitoCareX”), has received official trademark registration from the United States Patent and Trademark Office (USPTO) for its proprietary algorithm platform, MITOLINE™.
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding MitoCareX Bio
Sign Up For FreeTo access detailed company insights
MitoCareX Bio is a drug discovery company focused on developing novel therapies for hard-to-treat resistant cancers by targeting mitochondrial carriers. Utilizing their cloud-based computational chemistry platform and the MITOLINE algorithm, they model and predict small molecules that interact with these carriers. The company aims to address the li... Read More
